Dossier
RP1 (vusolimogene oderparepvec)
Coverage of RP1 (vusolimogene oderparepvec) in the Nexus archive.
- FDA Staff Unconvinced Drug for Melanoma Shows Benefit
FDA staff remains unconvinced that the melanoma drug candidate RP1 (vusolimogene oderparepvec) demonstrates sufficient benefit. The drug, previously rejected twice by the FDA, faces potential challenges at an upcoming FDA outside experts meeting.